To evaluate the pharmacokinetic Characteristics of two formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
52
Orally, one tablet at a time
The Third Hospital of Changsha
Changsha, Hunan, China
Maximum Plasma Concentration (Cmax) Of Jaktinib and its main metabolite ZG0244
Maximum Plasma Concentration (Cmax)
Time frame: up to 48 hours
Jaktinib and its main metabolite ZG0244 AUC(0-t)
Area under the concentration time curve from time 0 to time of the last quantifiable
Time frame: up to 48 hours
Jaktinib and its main metabolite ZG0244 AUC(0-inf)
Area under the concentration time curve from time 0 to infinity
Time frame: up to 48 hours
Jaktinib and its main metabolite ZG0244 Tmax
Maximum Plasma Concentration (Tmax)
Time frame: up to 48 hours
Jaktinib and its main metabolite ZG0244 t1/2
Half Life (t1/2)
Time frame: up to 48 hours
Adverse events
Time frame: Day 1 to Day 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.